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Lipocalin 2 (LCN2) is a secreted protein that belongs to the Lipocalins, a group of
transporters of small lipophilic molecules such as steroids, lipopolysaccharides, iron,
and fatty acids in circulation. Two decades after its discovery and after a high variety
of published findings, LCN2’s altered expression has been assigned to critical roles in
several pathological organ conditions, including liver injury and steatosis, renal damage,
brain injury, cardiomyopathies, muscle-skeletal disorders, lung infection, and cancer in
several organs. The significance of this 25-kDa lipocalin molecule has been impressively
increased during the last years. Data from several studies indicate the role of LCN2 in
physiological conditions as well as in response to cellular stress and injury. LCN2 in the
liver shows a protective role in acute and chronic injury models where its expression
is highly elevated. Moreover, LCN2 expression is being considered as a potential
strong biomarker for pathological conditions, including rheumatic diseases, cancer in
human organs, hepatic steatosis, hepatic damage, and inflammation. In this review, we
summarize experimental and clinical findings linking LCN2 to the pathogenesis of liver
disease.
Keywords: inflammation, liver, biomarker, alcoholic fatty liver disease, non-alcoholic steatohepatitis, matrix
metalloproteinases, liver failure, hepatic disease
INTRODUCTION
LCN2 has many synonyms including neutrophil gelatinase associated lipocalin (NGAL), 24p3,
oncogenic lipocalin, siderocalin, 25 kDa α2-microglobulin-related protein, and uterocalin. The
different names are justified by predicting functions of LCN2 or tissue in which the expression
was first detected. LCN2 belongs to the broad family of lipocalins that were first proposed to
have unifying functions in the transport of hydrophobic substances. This ever expanding family of
proteins share limited regions of sequence homology and a common tertiary structure architecture.
Details on the structure, characteristics, and most known functions of members of the lipocalin
family were highlighted in a previous report (Asimakopoulou and Weiskirchen, 2015).
Human LCN2 was initially isolated and purified by Kjeldsen and coworkers as a 25-kDa
neutrophil protein (Table 1), that is in part associated with gelatinase from human neutrophils
(Kjeldsen et al., 1993). One year later, the same group cloned the full length human LCN2 cDNA
and showed that this lipocalin is mainly expressed in myeloid cells (Bundgaard et al., 1994) and
later assigned to a cluster of at least three lipocalins on the long arm of human chromosome 9 by in
situ hybridization that is syntenic to a region of mouse chromosome 4 (Chan et al., 1994).
Abbreviations: AFLD, alcoholic fatty liver disease; AKI, acute kidney injury; ER; endoplasmic reticulum; FLD, fatty liver
disease; HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; LCN2, lipocalin 2; LPS, lipopolysaccharide(s); MCI, mild
cognitive impairment; MMP, matrix metalloproteinase; MS, multiple sclerosis; NAFLD, non-alcoholic fatty liver disease;
NASH, non-alcoholic steatohepatitis; NF-κB, nuclear factor-κB; NGAL, neutrophil gelatinase-associated lipocalin.
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TABLE 1 | Compilation of data on structure and function of LCN2.
Discovery LCN2 was first purified and identified from human phorbol myristate acetate-stimulated neutrophils as a gelatinase-associated
protein.
Terminology Acronyms for human LCN2 are: Neutrophil gelatinase-associated Lipocalin (NGAL), human neutrophil lipocalin (HNL), 25 kDa
α2-microglobulin-related protein, and Siderocalin. Further acronyms are oncogene 24p3 protein (24p3), Uterocalin, and 24 kDa
superinducible protein (Sip24) in mouse and Neu-related lipocalin (NRL) and α2u-globulin in rat.
Gene structure/chromosomal
localization
LCN2 is localized on the long arm of chromosome 9, (9q34.11) in a cluster of at least three lipocalins; the primary transcript is
3696-bp encompassing 7 exons and 6 introns.
Protein structure LCN2 is a secreted ∼25 kDa protein composed of 178 amino acids and belonging to the lipocalin family which transport small
hydrophobic molecules. These proteins share a similar three-dimensional fold composed of an eight-stranded, antiparallel
symmetrical β-barrel. One end of the barrel is open providing access to the binding site within the barrel cavity. LCN2 occurs in
monomeric and dimeric forms.
Biosynthesis/expression The steady state mRNA levels of LCN2 are high in bone marrow but not in peripheral leukocytes. High levels of LCN2 are found in
tissue (e.g., uterus, prostate, salivary gland, stomach, appendix, colon, trachea, and lung) that are often exposed to microorganisms
or glands that secrete to such tissues.
Functions Secreted transport protein, siderophore, modulator of innate immune response, binding partner of human gelatinase (MMP-9) and
bacterial catecholate-type ferric siderophores, delivers iron to the cytoplasma and acts as an activator/repressor of iron-responsive
genes.
Regulation LCN2 is an acute phase protein that is substantially activated by lipopolysaccharides and activated by the inducible transcription
factor NF-κB. Moreover, dexamethasone and retionoic acid increase expression of LCN2. Selected cytokines reported to induce
LCN2 expression are IL-6, IL-1β, IL-10, IL-17, TNF-α, and TGF-α.
Receptors Actually two LCN2 receptors are known, namely the low density lipoprotein-related protein 2 (LRP2, Megalin) and NGALR2 (solute
carrier family 22 member 17, SLC22A17, or 24p3R).
Target genes Transient overexpression experiments showed that LCN2 modifies expression of mesenchymal markers (e.g., vimentin, fibronectin),
E-cadherin, and the lipid droplet-associated protein PLIN5 (OXPAT).
Clearance/half life ∼10 min (monomeric form) and ∼20 min (dimeric form).
Presence in body fluids LCN2 is detectable in serum, plasma, urine, and tissue extracts.
Pathobiochemistry Increased expression during inflammatory activity in many organs (e.g., kidney, heart, brain, pancreas, lungs, and liver).
Animal models Lcn2-deficient mice in which exons 1–5 or exons 2–5 were replaced are viable but exhibit increased sensitivity to E. coli infections
and lipopolysaccharides showing that LCN2 is an important component of the innate immune systems and the acute phase
response. It limits bacterial growth by sequestering iron-laden siderophores. Respective mice show alterations in intracellular lipid
droplet formation.
The depicted information was taken from Triebel et al. (1992), Kjeldsen et al. (1993), Bundgaard et al. (1994), Axelsson et al. (1995), Garay-Rojas et al. (1996), Cowland and Borregaard
(1997), Goetz et al. (2002), Yang et al. (2002), Flo et al. (2004), Cai et al. (2010), Yang et al. (2009), and Asimakopoulou and Weiskirchen (2015).
The first critical roles given to LCN2 were proposed from its
“lipocalin structure” that is most closely related to the structures
of the epididymal retinoic acid-binding proteins and the major
urinary protein (Goetz et al., 2000). The typical unifying three
dimensional fold of lipocalins encompasses an eight-stranded,
anti-parallel, symmetrical β-barrel fold with a cylindrical shape
(Figure 1).
Later it was shown that murine and human LCN2 are both
iron-trafficking proteins that interfere with the activity of iron-
responsive genes (Yang et al., 2002). The initial finding that
LCN2 is involved in iron delivery pointed to a potential key role
of LCN2 in immunity. This assumption was further confirmed
in experiments showing that LCN2 has the capacity to limit
bacterial growth by sequestering the iron-laden siderophore
after infection in mice (Flo et al., 2004; Holmes et al.,
2005; Berger et al., 2006). After this very first allocation of
LCN2 as a significant factor in guaranteeing immune balance,
the repertoire of LCN2 functions was further expanded to
many biological processes, including inflammation, intoxication,
immune defense, organogenesis, and cancer.
In this review, we will summarize some of the major findings
of LCN2 in the pathogenesis of organ disease with a special
emphasis on inflammatory liver diseases.
REGULATION OF LCN2
LCN2 starts being expressed in the embryonic stage (Mallbris
et al., 2002) and it has been shown to be activated strongly
in inflamed organs such as liver, heart, lungs, bone marrow,
kidney, and spleen (Aigner et al., 2007; Borkham-Kamphorst
et al., 2011). LCN2 expression is also induced during neutrophil
maturation (Kjeldsen et al., 1993). It has been demonstrated
to decrease at an older age, especially in the kidney and liver.
Further, LCN2 is dramatically increased in cells by addition
of dexamethasone and retinoic acid (Garay-Rojas et al., 1996).
During bacterial infection, the expression of LCN2 has been
proved to be upregulated in several tissues such as liver (Xu
et al., 2015), diverse mucosal tissues (Kjeldsen et al., 2000),
lung (Chan et al., 2009), and epithelial tissue (Friedl et al.,
1999). In all these tissues LCN2 behaves as an acute phase
protein. At sites of infection LCN2 is secreted by neutrophils,
macrophages, activated leukocytes, and adipocytes (Kjeldsen
et al., 1993; Meheus et al., 1993; Flo et al., 2004). The different
reports unanimously show that LCN2 is either increased in
the tissue by several resident cell types or alternatively by
circulating immune cells that are recruited into the inflamed
tissue.
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In in vitro and in vivo experimentation, LCN2 was found
to be induced by several factors such as lipopolysaccharide
(LPS), cytokines, retinoic acid, growth factors, and insulin
(Meheus et al., 1993; Sorensen et al., 2003; Bu et al., 2006;
Sunil et al., 2007; Tan et al., 2009; Hamzic et al., 2013). LPS
has been shown to be a strong inducer of LCN2 in liver and
lungs (Sunil et al., 2007; Borkham-Kamphorst et al., 2013). The
stimulatory capacity of LPS in mice is extremely high when
compared to other hepatotoxins such as carbon tetrachloride and
Concanavalin A (Borkham-Kamphorst et al., 2013). There are
several other biomolecules and pathways known to contribute
to the expression of LCN2 in inflammatory cells, macrophage
cell lines, epithelial cells, breast cancer cell lines, and hepatocytes
(Meheus et al., 1993; Seth et al., 2002; Bu et al., 2006; Borkham-
Kamphorst et al., 2011; Kienzl-Wagner et al., 2015; Xu et al.,
2015). Cytokines that induce the expression of LCN2 include
the interleukins IL-6, IL-1β, IL-10, IL-17, tumor necrosis factor
(TNF-α), and tumor growth factor (TGF-α) (Sorensen et al.,
2003; Bu et al., 2006; Borkham-Kamphorst et al., 2011; Hamzic
et al., 2013; Vazquez et al., 2015; Xu et al., 2015). The nuclear
factor-κB (NF-κB) transcription activity seems to be the main
pathway involved in LCN2 stimulation (Bu et al., 2006). The close
linkage to the NF-κB pathway and diverse pro-inflammatory
cytokines that act through the activation of NF-κB was also found
in different models of hepatic injury (Borkham-Kamphorst et al.,
2011).
FIGURE 1 | The lipocalin fold. Members of the lipocalin family have a typical
eight-stranded, anti-parallel, symmetrical β-barrel fold structure. Depicted are
human and mouse LCN2, human retniol-binding protein 4 (RBP4), and human
liver fatty acid-binding protein (L-FABP). The depicted structures were
generated using the Ribbons XP software (version 3.0) and coordinates 3BX8,
3S26, 3FMZ, and 2LKK deposited in the RCSB Protein Data Bank (http://
www.rcsb.org). A size marker (10 Å) is given.
Up to date, LCN2 has been found to bind only on two
receptors. Hvidberg and colleagues first described that LCN2
binds to Megalin, representing a member of the low-density
lipoprotein receptor family (Hvidberg et al., 2005) while another
study described a 24p3R receptor of LCN2 that confers the ability
to undergo either iron uptake or apoptosis (Devireddy et al.,
2005). Although the concept that LCN2 does induce iron eﬄux
or stimulate apoptosis was somewhat challenged (Correnti et al.,
2012), a more recent fundamental study performed with human
homolog LCN2R (also known as SLC22A17) demonstrated that
the N-terminal part of this receptor has a soluble extracellular
domain that is intrinsically disordered with the capacity to
preferentially interact with LCN2 in its non-iron bound form
suggesting that this cellular receptor might discriminate between
the iron-free (apo-) and iron-bound (holo-) form of LCN2
(Cabedo Martinez et al., 2016).
LCN2 PATHOPHYSIOLOGICAL
EXPRESSION IN TISSUE
LCN2 is reported to be expressed in numerous pathological and
experimental-induced conditions in many organs and tissues
such as liver, kidney, lungs, bone, brain, and heart (Figure 2).
Several of the published findings on main organs are listed in
Table 2.
Here we will first focus on some of the most recent reports
on LCN2 expression and organ disorders to understand the
FIGURE 2 | Lipocalin 2 (LCN2) in organ damage. Representative
pathophysiological or malignancies conditions for which elevated LCN2
concentrations in representative organs are indicative are depicted.
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TABLE 2 | Selected experimental and clinical findings associated with altered LCN2 expression in organ disorders.
Organ Species Model/disease Method LCN2 expression Finding References
Kidney Mouse/
human
Chronic kidney
disease/
proteinuria
qRT-
PCR,
WB, IHC
Increased LCN2
expression
Induction of Ca2+-dependent ER stress causes
albumin to activate ATF4 expression, which in turn
induces LCN2 production leading to increased
apoptosis and tubulointerstitial damage
El Karoui
et al., 2016
Mouse Renal allograft
damage following
transplantation
ELISA,
qRT-PCR
Strong upregulation of
LCN2
LCN2 improved morphological and functional
damage by reducing apoptosis of tubular epithelial
cells and stimulating their proliferation
Ashraf et al.,
2016
Mouse Antibody-induced
glomerulonephritis
IHC,
ELISA
LCN2 expression is
increased in mice with
nephrotoxic nephritis
Renal binding of pathogenic antibodies stimulates
LCN2 expression
Pawar et al.,
2012
Human Acute kidney injury
(AKI)
ELISA Strong upregulation of
LCN2 in progressive AKI
Urinary high LCN2 expression indicates risk for
progression and death of AKI patients
Belcher et al.,
2014
Human
newborns
Acute kidney
injury/failure
ELISA,
WB
Upregulation of LCN2 in
serum and blood
LCN2 is a diagnostic marker for AKI in neonates Jin et al.,
2011
Heart Human/
children
Acute heart
failure/worsening
renal function
ELISA High plasma LCN2
concentration
Admission plasma LCN2 level can predict worsening
renal function in children hospitalized for acute heart
failure
Elsharawy
et al., 2016
Mouse,
rat
Heart
failure/cardiomyocyte
apoptosis
NA NA Recombinant LCN2 directly induces cardiomyocyte
apoptosis which occurs via a mechanism involving
elevated intracellular iron levels
Xu et al.,
2012
Mouse Hypoxia-induced
cardiomyocyte
apoptosis
qRT-
PCR,
WB
Transient overexpression
by transfection
Induced up-regulation of miR-138 inhibits the
hypoxia-induced cardiomyocyte apoptosis via
down-regulating expression of pro-apoptotic LCN2;
LCN2 is a direct target of miR-138
Xiong et al.,
2016
Brain Human Mild cognitive
impairment (MCI)
and Alzheimer’s
disease (AD)
ELISA LCN2 levels significantly
higher in MCI patients
compared to the healthy
control
Increased plasma LCN2 levels during MCI could be
helpful in predicting the progression from MCI to AD
Choi et al.,
2011
Human Depression ELISA Elevated plasma LCN2
levels in depressed
subjects
LCN2 plasma levels are increased in depressed older
persons, resistant to antidepressant medication and
age; plasma LCN2 is a possible biomarker for
late-life depression
Naudé et al.,
2013
Mouse/
human
Multiple sclerosis
(MS)
IF, IHC,
ELISA,
qRT-PCR
LCN2 expression
strongly induced after
murine MS model and in
human
blood-cerebrospinal fluid
samples of MS patients
LCN2 a valuable molecule for the diagnostics and
monitoring of MS
Marques
et al., 2012
Pancreas Human Pancreatitis ELISA Urinary LCN2 levels
associated with
increased severity and
mortality
LCN2 a promising diagnostic and prognostic factor
for severe acute pancreatitis in an early stage of the
disease
Lipinski et al.,
2015
Human Chronic
pancreatitis,
pancreatic cancer
ELISA LCN2 significantly
elevated in the pancreatic
juice of patients
LCN2 could help establish etiology for pancreatitis Kaur et al.,
2013
Lung Mouse LPS-induced
acute lung injury
ELISA,
WB,
qRT-PCR
LCN2 levels upregulated
in diseased mice
LCN2 is a promising in detection of experiment acute
lung injury
Zeng et al.,
2014
Human Sepsis-induced
acute respiratory
distress syndrome
qRT-PCR Significantly elevated
LCN2 mRNA expression
LCN2 with other neutrophil related genes
participates in neutrophil-related mechanisms in
progression to acute respiratory distress syndrome
Kangelaris
et al., 2015
Musculo-
skeletal
tissues
Human Rheumatoid
arthritis
ELISA LCN2 was highly
expressed in the synovial
fluids of patients
compared to healthy
controls
LCN2 is a possible diagnostic marker for rheumatoid
arthritis
Bläser et al.,
1995
(Continued)
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TABLE 2 | Continued
Organ Species Model/disease Method LCN2 expression Finding References
Skin Mouse Topical
psoriasiform skin
NA LCN2 enhances
expression of Th17
cytokines/chemokines
and antimicrobial
peptides
LCN2 potentiates the development of psoriasis Hau et al.,
2016
Cancer Human Brain tumor Zymography,
ELISA,
IHC
Great increase of LCN2 in
tumor tissue and clearing
after tumor resection
Useful predictor of the presence of brain tumors Smith et al.,
2008
Human Gastric cancer MMP-
9/LCN2
complex
zymography,
WB, IHC,
IF
Enhance expression of
MMP-9/LCN2 in cancer
tissue
Enhanced levels of MMP-9/LCN2 complex is highly
prognostic for worse survival in gastric cancer
patients
Kubben et al.,
2007
Human Pancreatic
adenocarcinoma
IHC,
ELISA,
qRT-
PCR,
WB
LCN2 overexpression in
pancreatic cancer lesions
LCN2 might participate in pancreatic cell
transdifferentiation and progress of cancer
Moniaux
et al., 2008
Human HCC IHC Upregulated LCN2
expression in HCC
significantly correlated
with unfavorable
clinicopathologic features
LCN2 could serve as prognostic factor and potential
therapeutic target in HCC
Zhang et al.,
2012
Human Endometrial
cancer
IHC LCN2 expression was
associated with VEGF-A
expression and distant
tumor recurrences
LCN2 expression is associated with aggressive
features and poor prognosis of endometrial cancer
Mannelqvist
et al., 2012
Human Breast cancer IHC,
ELISA
Elevated LCN2 levels
were found at advanced
breast cancer stages in
breast tissue and urine
LCN2 promotes breast cancer progression by
inducing EMT
Yang et al.,
2009
Mouse Breast cancer
model and cell
culture models
ELISA LCN2 contributes to early
events in metastasis,
induces EMT, enhances
migration and invasion
Tumor stroma-derived LCN2 promotes breast cancer
metastasis
Ören et al.,
2016
AD, Alzheimer’s disease; AKI, acute kidney injury; ELISA, Enzyme-linked immunosorbent assay; EMT, epithelial to mesenchymal transition; IF, immunofluoresence; IHC,
immuohistochemistry; MCI, mild cognitive impairment; MS, Multiple sclerosis; qRT-PCR, quantitative real time polymerase chain reaction; WB, Western blot.
possible major functions of LCN2 and subsequently highlight the
importance of LCN2 in the pathogenesis of hepatic disease.
During the last years, LCN2 has been well-studied as a
potential biomarker for kidney injury or to estimate the outcome
of respective diseases (Coca et al., 2008; Heyne et al., 2012;
Paragas et al., 2012; Barreto et al., 2014; Matsa et al., 2014). In one
multicenter, prospective cohort study, a significant correlation
between urinary injury biomarkers (LCN2, IL-18, KIM-1, L-
FABP, and albuminuria) and disease outcome was found in which
LCN2 only distinguished progression alone from no progression,
suggesting that LCN2 as other proteins with similar behavior
could potentially serve to identify patients at highest risk of
progression and death (Belcher et al., 2014). More recently a
systematic review and meta-analysis on LCN2 in acute kidney
injury (AKI) or failure investigating more than 50 studies
concluded that blood LCN2 could be used as a diagnostic marker
for AKI in newborns (Jiang and Cui, 2015). Moreover, several
investigators have suggested urinary LCN2 as an early diagnostic
marker in renal impairment and AKI in chronic cirrhosis (Gerbes
et al., 2011; Fagundes et al., 2012; Verna et al., 2012; Wong and
Murray, 2014).
In addition to acute injury in the kidney, another study
reported an active critical role of LCN2 activity in the formation
of chronic kidney disease (Viau et al., 2010). In this report, it
was found in experimental models of chronic kidney disease in
mice from different genetic backgrounds, that the severity of
renal lesions was strongly dependent on LCN2 that significantly
correlated with hyperproliferation and disease progression in
both mice and humans. Moreover, the authors found that LCN2
mediates the mitogenic effects of EGFR that critically predicts the
severity of renal lesions after nephron reduction. These findings
gave LCN2 a critical role in the pathogenetic pathways that
lead to progressive renal failure and cystogenesis (Viau et al.,
2010). In extension to their observation, the same group recently
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showed that ATF4 is mandatory for the efficient induction of
LCN2 in the course of albumin-induced tubular damage (El
Karoui et al., 2016). In this condition, the high concentration of
LCN2 induces endoplasmic reticulum stress-induced apoptosis
leading to chronic kidney disease, proteinuria and severe
tubulointerstitial damage, which ultimately leads to end-stage
renal disease (El Karoui et al., 2016). The authors proposed a
model of tubulointerstitial injury caused by proteinuria where
during endoplasmic reticulum (ER) stress, albumin activates
the activating transcription factor 4 (ATF4) which in turn
induces LCN2 production that leads further to apoptosis and
tubulointerstitial damage. Most interestingly, providing mouse
models and human clinical data, it was conclusively proved
that 4-phenylbutyric acid that is used as a drug in humans to
allow the kidneys to excrete excess nitrogen, has the ability to
reduce ER stress thereby preventing proteinuria-induced renal
lesions and LCN2 overexpression. The inhibition of LCN2 in
this pathway reduced mortality and protected kidneys from
degradation, morphological and functional (El Karoui et al.,
2016). Similarly, a crucial role of LCN2 was proven in a mouse
model of nephrotoxic nephritis in which the injection of LCN2
promoted inflammation, apoptosis, and exacerbated nephritis
(Pawar et al., 2012).
In contrast to these findings, another study investigating
acute allograft rejection in mice, showed that the treatment
with recombinant LCN2 after transplantation reduced the extent
of kidney allograft rejection, renal allograft damage, apoptosis
of tubular epithelial cells, and induced their proliferation. The
proliferation led to an amelioration of damage morphology and
improved allograft function (Ashraf et al., 2016). These two
studies paradigmatically demonstrate that LCN2 is a versatile
biomolecule with outstanding pathophysiological, diagnostically,
and potential therapeutic relevance.
The heart and kidney have numerous similarities
and their relationship makes it understandable that
renal dysfunction/failure often accompanies cardiac
dysfunction/failure and the opposite (Shah and Greaves,
2010). Except the significant role that LCN2 seems to play
in renal disorders, studies on cardiomyopathies indicate a
wider role of LCN2. So far it was known that acute heart
failure is frequently associated with worsening renal function
in adult patients. Although investigations on the role of LCN2
in the heart have only recently begun, a very recent report
showed that plasma LCN2 levels can also predict worsening
renal function in hospitalized children with acute heart failure
(Elsharawy et al., 2016). Mechanistically, a recent review on
cardiomyopathies discusses how LCN2 can regulate heart failure
based on iron overload and iron deficiency (Chan et al., 2015).
The authors highlight that LCN2 is a very critical factor involved
in regulating various cellular mechanisms including oxidative
stress, mitochondrial dysfunction, ER stress, and autophagy that
all can contribute to cardiac dysfunction when perturbed and
optimal iron levels are absent (Chan et al., 2015).
Based on the role of LCN2 in iron transport, it was also
speculated that circulating LCN2 levels may reflect the body’s
iron status in haemodialysis patients (Bolignano et al., 2009).
LCN2 leads to cardiomyocyte apoptosis by causing intracellular
iron accumulation (Xu et al., 2012). On the other side, the up-
regulation of the miR-138 gene inhibits the hypoxia-induced
cardiomyocyte apoptosis via down-regulating of LCN2 acting
pro-apoptotic (Xiong et al., 2016). All these data indicate that
LCN2 is a very sensitive regulator of cell survival and apoptosis in
cardiomyocytes. In addition, these strong indications of LCN2’s
correlation to heart disorders makes further elucidation of LCN2
role in heart failure a very interesting and crucial topic to study.
Several conflicting results on the role of LCN2 in
neurological processes are published. Some studies point to its
neurodeleterious effects, while others indicate neuroprotection.
In a clinical study that enrolled 41 patients with mild cognitive
impairment (MCI), 62 patients with Alzheimer’s disease and 38
healthy elderly control subjects, it was found that MCI, which
is a prodromal-inflammation stage of Alzheimer’s disease, is
correlated with elevated plasma LCN2 levels (Choi et al., 2011).
Depression was also associated with LCN2 plasma levels in a
cohort of 350 depressed persons that were compared to 129
non-depressed older subjects (Naudé et al., 2013). The study
further revealed that the concentration of LCN2 was higher in
patients with a recurrent depression compared to those with a
first episode and independent of antidepressant treatment. A
study performed in an experimental model of multiple sclerosis
(MS) in mice and also analyzing cerebrospinal fluid samples
taken from human patients suffering from MS showed increased
LCN2 levels in the active phases of experimental autoimmune
encephalomyelitis and in MS patients when compared to healthy
individuals. Remarkably, the increase of LCN2 levels in the
experimental animal model was reverted by the humanized
monoclonal antibody Natalizumab that in humans is used for
MS treatment supporting the notion that LCN2 measurement
should be included in the diagnostic panel of markers for MS
(Marques et al., 2012). However, the precise impact of LCN2 in
the brain is still in the very beginning and further studies are
required to unravel its roles in the nervous system.
Additionally, LCN2 has been studied in the endocrine gland
disorders. In 2013 a study had strongly suggested LCN2 in the
alkaline pancreatic juice as a marker for differentiating diseased
from non-diseased pancreas and that LCN2 could contribute to
understanding the etiology of pancreatitis (Kaur et al., 2013).
Similarly, a study investigating the urinary levels of LCN2 in
a cohort of more than 100 patients with inflammation of the
pancreas found that the levels of LCN2 correlated with the
severity of acute pancreatitis and mortality rate indicating that
LCN2 could also be useful as biomarker for acute pancreatitis
(Lipinski et al., 2015).
Preliminary studies performed in mice also point to a
diagnostic role of LCN2 in LPS-induced septic acute lung injury
(Zeng et al., 2014). In the same line, an investigation analyzing
early sequence of events leading to the development of the
acute respiratory distress syndrome, representing a common
complication of sepsis found that the mRNA levels of LCN2
and other genes involved in the initial neutrophil response are
upregulated in acute respiratory distress syndrome in respective
patients (Kangelaris et al., 2015). These studies on LCN2 show
that analyzing functional aspects of this lipocalin could also help
to understand the pathogenesis or progression of lung diseases.
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Moreover, strong indications of functions of LCN2 have
been identified in musculoskeletal diseases. Bläser and colleagues
reported in 1995 that very high concentrations of LCN2
were found in the synovial fluids (viscous fluid present in
the cavities of movable joints) of patients suffering from
inflammatory rheumatoid arthritis (Bläser et al., 1995). LCN2
was also proposed in a study analyzing a murine model of
cartilage degradation a biomarker to estimate the severity
of degeneration and inflammation (Wilson et al., 2008). In
addition, LCN2 transgenic mice were marked by a smaller
phenotype, presented bones micro-architectural changes in
both endochondrial and intramembranous bones, and further
showed a reduced deposition in the osteoblast bone matrix and
impairment in expansion of bone marrow cavity (Costa et al.,
2013).
Dysbalanced LCN2 expression has also been associated with
cancer formation and progression in several organs. According
to numerous studies in which LCN2 was quantitated by
immunological methods such as immunohistochemistry, ELISA,
gel zymography, and Western blots in urine, LCN2 has been
proposed as an early marker of bladder, brain and endometrial
cancer (Monier et al., 2000, 2002; Roy et al., 2008; Smith et al.,
2008; Mannelqvist et al., 2012). Moreover, it was suggested to
serve as a diagnostic marker for oesophageal and breast cancer
progression or metastasis, gastric cancer and pancreatic tumors
when measured as an individual biomarker or in a complex
with other proteins (Kubben et al., 2007; Zhang et al., 2007;
Moniaux et al., 2008; Yang et al., 2009; Du et al., 2011; Ören
et al., 2016). In renal and thyroid solid tumors, LCN2 showed
a positive correlation with malignant phenotypes (Iannetti et al.,
2008; Barresi et al., 2010, 2012a,b). In ovarian solid tumors, LCN2
was associated with cancer differentiation, whereas LCN2 was
also proved to be correlated with hepatocarcinoma and lung
tumor progression (Friedl et al., 1999; Zhang et al., 2012). Even
though LCN2 is suggested to have a role in the early stages of
tumor development or as a prognostic marker, there is an urgent
need for elucidating the role of LCN2 by studying its effects
on metastasis behavior. Of course, the multitude of pathological
events (cancer, inflammation, metastasis, organ failure) and
affected organs (kidney, liver, heart, brain, pancreas, muscle) that
give rise to alterations in LCN2 serum or urine levels may further
require the definition of clear cut-off values that are indicative for
a specific disease.
HEPATIC LCN2 EXPRESSION
During the last years, LCN2 has been studied widely as a
possible non-invasive biomarker for several organ disorders, as
outlined above. Hepatic expression of LCN2 in disease is the
most intensively studied chapter with almost 1/4 of the published
findings targeting the roles of LCN2 in liver homeostasis. The
liver is the vital organ for fat and carbohydrate metabolism.
It is the body’s production facility for many metabolites,
hormones, and proteins that also detoxifies substances and
excretes metabolites. Thus, any functional impairment in liver
affects undesirably the whole organism. Experimental and clinical
findings indicating altered hepatic LCN2 expression in numerous
disease conditions are given in Figure 3 whereas the most recent
findings are gathered in Table 3.
To sum up, alterations in LCN2 expression and functions
are reported in many hepatic conditions, including fatty liver,
hepatic inflammation, hepatitis C, hepatic regeneration, acute
and chronic liver injury, cirrhosis, and liver failure. In the
following we will discuss some of the most striking observations
that were placed in context with LCN2.
HEPATIC INJURY—INFLAMMATION
Based on experimental models of hepatic injury in which
mice received injections of carbon tetrachloride (CCl4) or rats
were subjected to bile duct ligation, a marked increase in
LCN2 expression was found (Borkham-Kamphorst et al., 2011).
The increase of LCN2 expression was correlated with liver
damage and was inducible in cultured hepatocytes by diverse
inflammatory stimuli, suggesting that LCN2 is as an early
biomarker of liver inflammation (Borkham-Kamphorst et al.,
2011; Labbus et al., 2013). In line, Ariza and colleagues found
in a cohort of more than 700 patients with cirrhosis that urine
LCN2 was markedly increased in the patients when compared to
healthy control samples, establishing urine LCN2 as a prognostic
marker of cirrhosis (Ariza et al., 2016). Most interestingly, in this
study it was demonstrated that the measurement of urine LCN2
had a better predictive power than the measurement of serum
LCN2 in discriminating acute-on-chronic liver failure (ACLF)
patients from cirrhotic patients with acute decompensation. The
authors suggested that this is due to the fact that the association
between urine LCN2 and ACLF was not exclusively related to
kidney function and that further urine but not serum LCN2 is
independently associated with ACLF.
Similarly, the quantities of LCN2 in fresh spot urine samples
were found to correlate with fibrosis score and reflected the
increased activity of matrix metalloproteinase-9 (MMP-9) in
FIGURE 3 | LCN2 in the pathogenesis of liver diseases. LCN2 is a
versatile adiponectin that influences all kinds of liver diseases. For more details
on experimental and clinical findings associated with altered LCN2 expression
refer to Table 3.
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TABLE 3 | Selected experimental and clinical findings associated with altered LCN2 expression in liver.
Species Model/disease LCN2 detection
method
LCN2 expression Finding References
Rat Acute and chronic liver injury
(CCl4, bile duct ligation)
IHC, WB,
qRT-PCR
Elevated expression of LCN2 in
hepatocytes after injury
LCN2 overexpression can indicate
liver damage. Suggested as a
biomarker of early hepatic injury
Borkham-Kamphorst
et al., 2011
Mice (WT and
Lcn2−/−)
Acute liver injury (LPS,
ConA, bile duct ligation)
ELISA, WB,
qRT-PCR
Liver injury induced LCN2
upregulated expression
LCN2 is a trustworthy biomarker
of hepatic damage and serves
possible protective role in liver
Borkham-Kamphorst
et al., 2013
Lcn2-
deficient
mice
Hepatic inflammation (LPS) NA NA LCN2 is an essential factor for
regulation of inflammatory
process manifestations during
liver injury
Labbus et al., 2013
Human Hepatic cirrhosis ELISA Increased expression in patients Urine LCN2 is a prognosis marker
of cirrhosis
Ariza et al., 2016
Rat Chronic rejection Mass
spectrometry
LCN2 elevation in the chronic
rejection group
LCN2 potential prognostic
markers for predicting chronic
rejection after liver transplantation
Wei et al., 2015
Human Chronic HCV-induced
fibrosis
ELISA, WB,
Gelatin
zymography
Urine LCN2 levels higher in
patients with fibrosis/cirrhosis in
the same line as
MMP-9/MMP-2 ratio
Urinary LCN2 is a novel marker of
hepatic fibrosis by reflecting urine
MMP-9 activity in chronic
hepatitis C
Kim et al., 2010
Human Acute liver failure and
chronic liver failure
ELISA Baseline LCN-2 serum
concentrations were
significantly increased among
acute liver failure patients as
compared with chronic hepatic
failure
LCN2 useful to discern acute
from chronic hepatic failure and to
monitor severity of the disease
Roth et al., 2013
Human Chinese patients with
NAFLD
ELISA Circulating LCN2 elevated in
patients compared healthy
controls
Serum LCN2, correlates with
inflammation and insulin
resistance, and is correlated with
disease progression
Ye et al., 2014
Human Obese women with NAFLD ELISA Liver LCN2 protein and gene
expression were higher in
NAFLD than obese women
without NAFLD
LCN2 related to NAFLD and liver
damage
Auguet et al., 2013
Human NAFLD patients ELISA Urinary LCN2 levels correlated
with body mass index, glucose,
and insulin levels in patients
with steatosis; LCN2 levels
correlated also with fibrosis
stage and cirrhosis
LCN2 has a novel association
between urinary levels and
hepatocellular injury in these
patients
Tekkesin et al., 2012
Mice (WT and
Lcn2−/−)
High fat diet
induced-NAFLD
WB The molecular disruption of
Lcn2 in mice resulted in
significantly potentiated
diet-induced obesity,
dyslipidemia, fatty liver disease,
and insulin resistance
LCN2 contributes in regulation of
lipid metabolism and insulin
resistance
Guo et al., 2010
Mice (WT and
Lcn2−/−)
High fat diet
induced-obesity
NA LCN2 supports function of
PPAR-γ ligands
LCN2 regulates hepatic
lipogenesis by affecting PPAR- γ
expression
Jin et al., 2011
Rats High fructose diet-induced
NAFLD
WB, qRT-PCR, IF,
ELISA
Overexpression of LCN2 in
NAFLD mice
LCN2 to be correlated to
inflammation, mitochondrial
malfunction, oxidative stress and
liver protective qualities
Alwahsh et al., 2014
Mice (WT and
Lcn2−/−)
MCD diet-induced-NASH WB, qRT-PCR, IF Overexpression of LCN2 in
NASH mice; LCN2 regulates
PLIN5 expression in
hepatocytes
LCN2 regulates liver lipid
homeostasis by partially
regulating PLIN5 expression
Asimakopoulou et al.,
2014
Mice Genetically induced NASH
with fatty liver Shionogi mice
qRT-PCR, IHC NASH mice presented higher
LCN2 expression
LCN2 has a key role in NASH
development
Semba et al., 2013
(Continued)
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TABLE 3 | Continued
Species Model/disease LCN2 detection
method
LCN2 expression Finding References
Human Alcoholic fatty liver disease
(AFLD) patients
ELISA Increased hepatic LCN2 in
AFLD patients compared to
patients with alcoholic cirrhosis
or simple steatosis
LCN2 drives ethanol-induced
neutrophilic inflammation and
participates in the development of
AFLD; pharmacological
neutralization of LCN2 is a
potential treatment
Wieser et al., 2016
Mice (WT and
Lcn2−/−)
MCD diet-induced-NASH WB, qRT-PCR, IF LCN2 elevated levels after MCD
diet for 4 weeks induced
intense leukocyte recruitment
LCN2 has an hepatoprotective
role as it is required in neutrophil
trafficking to liver
Asimakopoulou et al.,
2016
Human Patients who underwent
curative resection of HCC
IHC The expression levels of LCN2
and its receptor were both
up-regulated in HCC tissues;
high expression correlated with
shorter overall survival
Expression of LCN2 and its
receptor might serve in HCC
prognosis and therapy
Zhang et al., 2012
Human HCC patients ELISA Increased LCN2 expression in
patients with HCV and HCC
LCN2 can be used as a future
diagnostic marker with better
sensitivity and specificity than
MMP-9 for the progression of
HCC
El Moety et al., 2013
Mice (WT and
Lcn2−/−)
Bacterial infection or partial
hepatectomy
ELISA Lcn2-deficient mice
demonstrated increased
susceptibility to infection and
reduced liver regeneration after
hepatectomy
Hepatocytes are the major cell
type responsible for LCN2
production after bacterial infection
and hepatectomy;
hepatocytic-derived LCN2 has
important hepatoprotective roles
in those conditions
Xu et al., 2015
ConA, Concanavalin A; ELISA, Enzyme-linked immunosorbent assay; HCC, hepatocellular carcinoma; IF, immunofluoresence; IHC, immunohistochemistry; LPS, lipopolysaccharide;
MCD, Methionine-choline-deficient diet; NASH, non-alcoholic steatohepatitis; PLIN5, Perilipin 5; PPAR- γ , Peroxisome proliferator-activated receptor-γ ; qRT-PCR, quantitative real time
polymerase chain reaction; WB, Western blot.
urine in patients suffering from chronic hepatic C infection
(Kim et al., 2010). Unfortunately, this study correlated LCN2
levels only to the grade of fibrosis as assessed according to the
METAVIR fibrosis score in only 18 patients that had no or mild
fibrosis and 24 patients with significant fibrosis, while the amount
of inflammation (i.e., the activity) within the diseased liver was
not considered. In a subsequent study, that included a total of
n = 192 patients with chronic liver diseases of any etiology
and healthy controls showed that LCN2 is a reliable indicator
of liver damage that is positively correlated with inflammation,
but is not correlated with the degree of liver fibrosis per se
(Borkham-Kamphorst et al., 2013). In line with these findings,
it was proposed that LCN2 serum levels may be diagnostically
useful to discern acute from chronic hepatic failure (Roth et al.,
2013). However, a recent report showed that LCN2 in plasma
and urine are both suitable as independent predictive factors of
acute-on-chronic liver failure that correlates with liver failure and
systemic inflammation (Ariza et al., 2016).
Compared to normal controls, the livers of LCN2 deficient
mice were more injured when exposed to short term application
of CCl4, LPS and Concanavalin A, or subjected to bile duct
ligation. This was reflected by elevated levels of aminotransferases
and increased expression of inflammatory cytokines such as IL-
1β, IL-6, and TNF-α which in turn resulted in prolonged NF-
κB activation and sustained activation of STAT1, STAT3, and
JNK pathways in hepatocytes. Based on these findings, it was
supposed that as a counterpart to all these observations LCN2
has also hepatoprotective roles in phases of acute liver injury
(Borkham-Kamphorst et al., 2013). In the same study, it was
noted that hepatocytes of mice that lack LCN2 showed lipid
droplet accumulation and increased apoptosis giving a slight
hint of LCN2 as a modulating factor in lipid metabolism. In
the same study it was demonstrated that although patients with
chronic liver disease exhibited significantly higher concentrations
compared to healthy volunteers, the levels of LCN2 were not
suitable to discriminate between non-cirrhotic and cirrhotic
liver-diseased patients, suggesting that LCN2 levels provide no
correlation to the degree of liver fibrosis but provide a significant
positive correlation to inflammation.
FATTY LIVER DISEASE AND
STEATOHEPATITIS
Fatty liver disease (FLD) is the abnormal hepatic fat accumulation
(steatosis) that can also progress to fat accumulation combined
with inflammation in the liver (steatohepatitis). In principle,
there are three types of fatty liver. First, non-alcoholic fatty
liver disease (NAFLD), a condition with prevalence up to 1–
3 in western societies, where liver accumulates fat reaching
more than 5% of the total liver weight because of factors
independent of excessive alcohol intake (Baumeister et al., 2008;
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Bellentani et al., 2010; Fotbolcu and Zorlu, 2016). NAFLD is
not just a liver disease as it is associated with cardiovascular
disease, chronic kidney disease, type 2 diabetes, obesity, and
dyslipidemia (Fotbolcu and Zorlu, 2016). NAFLD can progress to
non-alcoholic steatohepatitis (NASH) where lipid accumulation
is accompanied by inflammation (steatohepatitis) that cause
irreversible hepatic damage (Neuman et al., 2016). Second,
alcoholic fatty liver disease (AFLD), the second most common
fatty liver condition, is as the name reveals the toxic accumulation
of fat as a result of long-term excessive alcohol consumption.
AFLD appears with smaller prevalence than NAFLD, but in
patients both conditions lead to hepatic structural changes,
obesity, metabolic disorders, and abnormal glucose tolerance
(Reddy and Rao, 2006; Kotronen et al., 2010; Lívero and Acco,
2016). The third most widespread form of FLD is the acute
fatty liver of pregnancy, a life threatening complication, for both
mother and fetus, which develops in the last months of pregnancy
(Zhang Y. P. et al., 2016).
Although there is a high prevalence of all kinds of FLDs in
modern societies, no reliable non-invasive method for disease
assessment has been identified yet. Therefore, the histological
examination of liver tissue after liver biopsy remains still the gold
standard for evaluating the degree of hepatic necro-inflammation
and fibrosis (Fierbinteanu-Braticevici et al., 2010). During the
last years, the increase of the enzyme alanine transaminase (ALT)
was commonly measured clinically as a non-invasive biomarker
for FLD assessment. However, the specificity of this marker for
FLD is rather low, because it is also indicative of hepatocellular
abnormalities without distinction between damage and steatosis
(Musana et al., 2004; Myers, 2009; Barr et al., 2010). There are
numerous studies available that correlated LCN2 with obesity,
insulin resistance and diabetes (Yan et al., 2007; Law et al., 2010)
rendering LCN2 as a possible biomarker for assessment of FLD.
A study that investigated the development of NAFLD in
Chinese subjects revealed a close correlation of serum LCN2
with the progression of the disease and the occurrence of insulin
resistance (Ye et al., 2014). Similarly, the circulating levels of
LCN2 and hepatic expression of LCN2 were significantly higher
in female NAFLD patients than in women with severe obesity
with non-significant liver disease (Auguet et al., 2013), again
suggesting LCN2 as a good biomarker for assessment of NAFLD.
This study also showed that the administration of TNF-α, IL-6,
resistin, and adiponectin stimulated expression in HepG2 cells,
confirming previous reports demonstrating that the expression
of LCN2 is moderated by pro-inflammatory triggers (Borkham-
Kamphorst et al., 2011). Moreover, in another study analyzing
adult patients with NAFLD, urinary LCN2 levels correlated well
with the body mass index, insulin resistance, and lipid profiles
(Tekkesin et al., 2012).
In experiments in Lcn2-deficient mice fed with a high fat diet
to induce experimental steatosis, it was shown that the lack of
LCN2 expression significantly potentiated diet-induced obesity,
dyslipidemia, FLD, and insulin resistance (Guo et al., 2010). In
a subsequent study, it was demonstrated that LCN2 is a critical
modulator of PPAR-γ activation at the level of the recruitment
of coactivators/corepressors thereby impacting adipogenesis and
lipogenesis in adipose tissue and liver (Jin et al., 2011).
The impact of LCN2 for the formation of obesity,
inflammation, and obesity-associated metabolic dysfunction
was also shown in rat models after feeding with a high fructose
diet for 4–8 weeks. As in other models tested, the expression
of LCN2 correlated with hepatic inflammation, mitochondrial
malfunction, and oxidative stress (Alwahsh et al., 2014). We have
demonstrated in a nutritional mouse model of NAFLD and in
primary hepatocyte cell culture that LCN2 is directly linked to
the intracellular formation and accumulation of hepatic lipid
droplet accumulation partly via regulation of the lipid droplet
protein Perilipin 5 (Asimakopoulou et al., 2014). Comparative
analysis of wild type and Lcn2 deficient mice revealed that the
Lcn2 lacking mice accumulated more lipids in their livers when
fed a Methionine- and Choline-deficient diet (Asimakopoulou
et al., 2014). Again, this finding indicates that LCN2 has an
essential function in liver homeostasis and lipid metabolism
(Figure 4).
Moreover, our study has shown that LCN2 is able to directly
influence the expression of this lipid-droplet protein that is
essential in maintaining the balance between lipogenesis and
lipolysis and also of fundamental importance in fatty acid
oxidation. Interestingly, Semba and colleagues found in the Fatty
liver Shionogi (FLS) mice strain that are genetically programmed
to develop NASH that LCN2 is directly linked to the pathogenesis
of NASH. In addition, this study showed that LCN2 is primarily
expressed by hepatocytes present in inflammatory cell clusters
(Semba et al., 2013). Complementary data have suggested that
the injury-induced upregulation of LCN2 is a kind of intrinsic
“help me” signal (Figure 5) that might be relevant to recruit
inflammatory cells into the injured tissue (Asimakopoulou et al.,
2016).
After the finding that elevated LCN2 in circulation contributes
to the progression of NAFLD (Ye et al., 2014), alcohol-
related steatohepatitis was very recently shown also to closely
relate to LCN2 levels (Wieser et al., 2016). In the respective
study, the authors showed that Lcn2-deficient mice treated
with ethanol presented less severe liver injury histologically
and biochemically than the wild type mice. Reduced injury,
according to ALT levels, was presented as well in wild type
mice after LCN2 was neutralized before ethanol treatment
with an LCN2 specific antibody. In addition, the control
mice fed with ethanol showed increased LCN2 expression that
was mainly localized to leukocytes, especially neutrophils and
to a lower content in monocytes and Kupffer cells (Wieser
et al., 2016). Most interestingly, adoptive transfers revealed
that neutrophil-derived LCN2 is critically involved in hepatic
neutrophil immigration chronic alcoholic exposure, suggesting
that the neutralization of LCN2 in alcoholic liver disease might
be a promising therapeutic option to interfere with hepatic
inflammation (Wieser et al., 2016). In parallel to this, we showed
previously that during hepatic inflammation, the recruitment
of leukocytes/neutrophils as indicated by CD45 mRNA content
and Myeloperoxidase activity were significantly lower in Lcn2
deficient mice compared to wild type mice (Asimakopoulou
et al., 2016). In the same report we demonstrated that
wild type mice after LPS treatment for 6 h recruited more
Myeloperoxidase positive neutrophils when compared to LCN2
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FIGURE 4 | LCN2 and fat metabolism. A recent concept suggests that LCN2 is a key factor in controlling intracellular fat metabolisms in hepatocytes by regulating
expression of the lipid droplet protein PLIN5/OXPAT. (A) The concept is majorly based on the finding that mice lacking LCN2 accumulate more lipids in the liver and
show more hepatic damage and inflammation when fed a methionine-choline deficient diet (MCD) representing a nutritional model of NASH. (B) In the respective
study, it was proposed that LCN2 imports lipids into hepatocytes either via specific receptors (e.g., LCN2R) or unknown endocytosis pathways. Within the cytoplasm,
the LCN2/lipid complexes are first packed into endosomes whose slightly acidified microenvironment causes LCN2 to dissociate from the lipids. The lipids then move
into the cytoplasm, where they are coated by PLIN5/OXPAT protecting them from intracellular degradation and oxidation. LCN2 may be recycled and secreted.
PLIN5/OXPAT itself is up-regulated by PPAR-γ that is stimulated by the higher cytoplasmic fat content that is the consequence of facilitated lipid import by LCN2.
Together, the suspected interaction of LCN2, PPAR-γ, and PLIN5/OXPAT presents a complex network that affects lipid metabolism, glucose homeostasis, and
adipogenesis. In the presence of LCN2, intracellular concentrations of free reactive lipid species may be reduced and the overall inflammatory responses suppressed.
Contrarily, in the absence of LCN2, the concentration of free fatty acids within the cytosol is increased predisposing for inflammation and steatosis.
nulls, once again supporting the idea that LCN2 is critical
for leukocyte and neutrophil recruitment (Asimakopoulou
et al., 2016). The impact on migration and chemotaxis on
polymorphonuclear neutrophils was previously demonstrated
in mouse models in which the injection of LCN2 stimulated
the mobilization of neutrophils (Schroll et al., 2012). All these
data indicate that LCN2 acts as a paracrine chemoattractant
that modulates neutrophil trafficking to the liver and other
organs.
HEPATOCELLULAR CARCINOMA AND
HEPATITIS C
Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease worldwide, leading to end-stage cirrhosis, and
development of hepatocellular carcinoma (HCC). In 2010
urinary LCN2 levels were correlated to hepatic fibrosis and
cirrhosis in HCV patients (Kim et al., 2010). Shortly after,
an additional investigation demonstrated that LCN2 levels was
Frontiers in Physiology | www.frontiersin.org 11 September 2016 | Volume 7 | Article 430
Asimakopoulou et al. LCN2 in Hepatic Disorders
FIGURE 5 | Elevated hepatic LCN2 expression is a physiological indicator of hepatic inflammation. After acute inflammatory stimulus (1), the liver
synthesizes and secretes large quantities of LCN2 (2). This physiological response indicates that the liver is inflamed and needs help (3). As a consequence of the
emitted “help me” signal, inflammatory blood cells that are necessary to begin the repair are recruited (4) and infiltrate the liver (5). The infiltrating cell populations help
to destroy and clear infectious particles (6) and are helpful in restoring tissue homeostasis (7). For more details about this hypothesis are given elsewhere
(Asimakopoulou et al., 2016).
elevated in HCC tissues and that both higher LCN2 and LCN2R
expression correlated with shorter overall survival in HCC
patients (Figure 6; Zhang et al., 2012).
Equally, LCN2 expression in patients with HCV and HCC is
significantly increased (El Moety et al., 2013) proposing LCN2
as a reliable diagnostic marker for HCC progression. In this
regard it should be mentioned that patients suffering from HCC
are nowadays treated with hepatectomy, a surgical procedure
of liver resection to remove hepatic tumors. This procedure is
only possible because the liver is the only visceral organ that
possesses a remarkable capacity to regenerate. In murine models
of partial hepatectomy both Xu’s and Kienzl-Wagner’s teams
demonstrated dramatic elevation of hepatic and serum LCN2
(Kienzl-Wagner et al., 2015; Xu et al., 2015). Xu et al. showed
that the liver and specifically the hepatocytes are the main source
of LCN2 responsible for the highly elevated expression of LCN2
after hepatectomy leading to a significant increase in circulating
LCN2 levels for up to 24 h after hepatectomy (Xu et al., 2015).
This finding indicates that LCN2 could serve as a biomarker
for liver regeneration, however further experimentation is still
necessary to elucidate the role of LCN2 in liver hepatectomy and
regeneration.
DIAGNOSTIC VALUE OF LCN2
In the reported findings described above, LCN2 is shown to be
directly linked to several hepatic disorders in both humans and
animals. Alterations in LCN2 expression are demonstrated in
numerous models of hepatic pathogenesis conditions such as
acute and chronic liver injury, inflammation, oxidative stress,
mitochondrial dysfunction, bacterial infections, hepatitis C-
induced fibrosis, liver failure, obesity, NAFLD, NASH, AFLD,
HCC, and rejection after liver transplantarion (cf. Table 3).
Serum LCN2 could serve as a valuable biomarker of early
stage hepatic damage (Borkham-Kamphorst et al., 2011, 2013).
The measurement of LCN2 in urinary samples could be useful to
predict the outcome of cirrhosis, liver transplantation rejection,
and hepatic fibrosis (Kim et al., 2010; Wei et al., 2015; Ariza
et al., 2016). Clinical data and in vivo models of FLD (NASH,
NAFLD, AFLD) showed that elevated LCN2 levels are suitable
to mirror hepatic lipid abnormalities, inflammatory response,
mitochondrial malfunction, progress of FLD, and HCC (Guo
et al., 2010; Zhang et al., 2012; El Moety et al., 2013; Semba
et al., 2013; Asimakopoulou et al., 2014; Wieser et al., 2016).
Since LCN2 is being proved to mediate hepatic function under
multiple conditions, several studies during the last years have
been focussed on the development of sensitive detectionmethods
for LCN2. The mainly applied methods used for LCN2 detection
include ELISA, Western blots and immunostainings. All these
methods need specific LCN2 antibodies which have been
available from a variety of pharmaceutical companies. We have
previously listed the most common antibodies and systems used
in research nowadays for the detection of LCN2 (Asimakopoulou
and Weiskirchen, 2015). Most popular for quantification are
diverse ELISA tests that have been proved to be the most sensitive
and quick method to detect LCN2 elevation in early stages and
conditions of experimental and clinical liver disease including
FLD, NASH, and HCC.
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FIGURE 6 | Association of LCN2 and LCN2R expression with conventional clinicopathological HCC parameters. An association study investigated the
clinical significance of LCN2 and LCN2R in 138 patients who underwent curative resection of HCC. In conclusion, this study showed that the expression of both
genes is correlated (r = 0.89; P < 0.001) and are up-regulated in HCC tissue and associated with vascular invasion status (P = 0.03) and TNM classification stage of
malignant tumors (P = 0.004) that consider characteristics of the original primary tumor (T), the involved regional lymph nodes (N), and the occurrence of distant
metastasis (M). In addition, the expression of both genes correlated well with tumor recurrence (P < 0.001), poor prognosis (P < 0.003), and overall survival rates (P <
0.001), suggesting that LCN2 and LCN2R expression are suitable prognostic factors and potential therapeutic targets in HCC. Details of this study are given
elsewhere (Zhang et al., 2012).
However, there are actually many established biomarkers
available for each of these diseases and it is too early to estimate
the diagnostic and prognostic significance of LCN2 for daily
clinical routine. It will be exciting to follow up if LCN2 will be
added to the list of biomarkers suitable in HCC diagnosis and
which superior insights in HCC development or progression will
arise from LCN2 measurements that are not already disclosed by
other serum markers such as α-fetoprotein (AFP), M39, M65,
soluble CD163, or others that are already in use as tissue- or
serum-associated HCC biomarkers (Waidmann et al., 2013;
Morris et al., 2014; Chauhan and Lahiri, 2016).
LCN2 IN THERAPY
Many of the clinical conditions mentioned above that lead to
hepatic malfunction or damage are associated with a significant
upregulation of LCN2 expression in serum, urine, and/or liver
tissue. Actually, there are many ongoing studies that analyse the
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precise molecular activities of LCN2 during disease progression.
Recent studies performed in human kidney cells (i.e., HK-2)
have shown that the application of recombinant LCN2 proteins
induces excessive autophagy suggesting that LCN2 may have
tremendous effects in AKI (Zhang W. et al., 2016). In contrast,
protective effects of LCN2 were demonstrated in a mouse model
of nephrotoxic serum nephritis (Eller et al., 2013). Likewise,
a study that was conducted in myoblastic rat cardiomyocytes
(i.e., H9c2) showed that the treatment with recombinant LCN2
inhibited autophagy (Chan et al., 2016). These contradictory
findings indicate that LCN2 might have both protective as well
as pathogenic activities. These double-edged biological properties
may render therapeutic approaches complicated.
In regard to the liver, the chronic infusion of LCN2
exacerbated liver injury in two different models (i.e., MCD
and high fat high cholesterol diet), while at the same time the
observed hepatic injury in mice that were deficient for LCN2 was
markedly reduced after feeding respective diets (Ye et al., 2016).
Further analysis in this study showed that the inflammatory
activities of LCN2 are mediated via induction of the chemokine
receptor CXCR2 (formerly known as Interleukin 8 receptor, beta)
that transduces its signals through a G-protein-activated second
messenger system. Similarly, a pivotal and causal role of LCN2
was shown in cell models and animal models of AFLD (Cai
et al., 2016). However, there are also other disease conditions
in which this lipocalin protects the liver from acute liver injury
(Borkham-Kamphorst et al., 2013), again demonstrating the
versatile activities of LCN2.
Although it is now well-established that LCN2 has
fundamental modulator activities during hepatic insult, there
is still some work that remains to be done prior announcing
LCN2 as a therapeutic target. Currently, initial studies that use
anti-LCN2 antibodies (Tarín et al., 2016), siRNAs or shRNAs
targeting LCN2 (Volpe et al., 2013; Miyamoto et al., 2016),
specialized nanoparticle-based theranostic agents (Guo et al.,
2016), or modulators that impacts LCN2 receptor expression
(Cui et al., 2008) in different settings are initiated. In addition,
the design of therapeutic small-molecule inhibitors for LCN2
was recently proposed (Suk, 2016). These molecules might be
beneficial to target de novo LCN2 expression or its interaction
with its cognitive receptors. Therapeutic strategies are nowadays
tested in cell culture and preclinical models, but none of these
has been tested in clinical studies so far.
CONCLUDING REMARKS
The lipocalin 2 protein was initially proposed to represent
a secretory protein that is involved in the transportation of
hydrophobic molecules, including steroids, retinoids, hormones,
and lipids. Several years later, it has been promoted as a
multifunctional siderophore that is involved in innate immunity
by sequestering iron that in turn limits bacterial growth. A wide
variety of studies have shown that the expression of this lipocalin
is significantly altered in the pathogenesis of organ damage
affecting kidney, heart, brain, pancreas, and lungs. In this review,
we have summarized experimental and clinical findings linking
LCN2 to liver disorders. It is obvious that LCN2 is significantly
upregulated during phases of hepatic injury. In line with this
assumption, numerous studies correlated LCN2 with general
hepatic injury, inflammation, infection, cirrhosis, and fatty liver
disorders. In all these pathological states LCN2 expression seems
to be highly elevated, underpinning the notion that this lipocalin
is a good biomarker candidate for a large variety of hepatic
insults. Experimental findings have shown that the loss of LCN2
is correlated with a higher susceptibility to bacterial infections
and more severe hepatic damage after challenge with appropriate
hepatotoxins. Nowadays, several diagnostic test systems for
detecting and quantification of LCN2 in urine, serum, plasma
and tissue extracts are on the way to be incorporated into the
routine diagnostics. Under some conditions, the measurement of
urine LCN2 could more accurately reflect systemic inflammation
or disease progression than serum LCN2. However, although the
knowledge in LCN2 in liver biology has increased dramatically
during the last years, there is still a mandatory need for
studies that further characterized LCN2 and its pathways
in the initiation, progression and potentially regression of
hepatic lesions. These studies will potentially lead to novel
therapeutic avenues or drugs that might be beneficial to interfere
with progression or foster regression of inflammatory hepatic
disease.
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